Every 10-Q that Enanta Pharmaceuticals, Inc (ENTA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ENTA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ENTA filings page.
Enanta Pharmaceuticals, Inc. reported royalty revenue of $14,359 for the quarter and $50,133 for the nine months ended June 30, 2026, essentially flat year-to-date versus 2025 but lower in the quarter on reduced HCV sales from AbbVie’s MAVYRET/MAVIRET regimen.
Research and development expenses fell to $22,126 for the quarter and $62,428 year-to-date, down sharply as RSV clinical spending declined, while immunology and early discovery investment increased. General and administrative expenses also declined to $9,469 for the quarter and $28,046 year-to-date, reflecting lower stock-based compensation and legal costs.
Net loss narrowed to $19,501 for the quarter and $44,530 for the nine months, compared with $18,255 and $63,189 in 2025. Enanta held $211,493 in cash, cash equivalents and marketable securities and expects this, plus retained HCV royalties, to fund operations into fiscal 2029. The OMERS royalty sale liability stood at $125,073, with an effective imputed interest rate of about 12.8%, and the company added a $75.0 million at-the-market equity facility for additional financial flexibility while advancing RSV and immunology programs.
Enanta Pharmaceuticals reported royalty-based revenue of $17.2 million for the three months ended March 31, 2026, up from $14.9 million a year earlier, driven by higher MAVYRET/MAVIRET sales at AbbVie. Net loss narrowed to $13.1 million from $22.6 million as research and development spending fell to $19.4 million and general and administrative costs declined to $9.6 million.
For the six-month period, revenue reached $35.8 million and net loss was $25.0 million. The company ended the quarter with $227.0 million in cash, cash equivalents and marketable securities and expects this, plus its retained share of HCV royalties, to fund operations into fiscal 2029. Enanta continues to advance wholly owned RSV and immunology programs, including Phase 2 RSV candidate zelicapavir and a new Phase 1 KIT inhibitor, while carrying a royalty sale liability of $128.8 million related to its OMERS transaction.
Enanta Pharmaceuticals reported royalty revenue of $18.6 million for the quarter ended December 31, 2025, up from $17.0 million a year earlier, driven by higher HCV sales of MAVYRET/MAVIRET from AbbVie.
Research and development expenses fell to $20.9 million from $27.7 million, mainly as RSV trials wound down, while general and administrative expenses decreased to $9.0 million from $12.8 million due to lower stock-based compensation and legal costs. Net loss narrowed to $11.9 million from $22.3 million, or $0.42 per share versus $1.05 per share.
Enanta closed an October 2025 public offering of 7.5 million shares at $10.00, generating $69.9 million in net proceeds. As of December 31, 2025, cash, cash equivalents and marketable securities totaled $241.9 million, which the company believes will fund operations into fiscal 2029 while it advances RSV antivirals and multiple immunology programs.
Enanta Pharmaceuticals reported stable royalty-driven revenue but continued operating losses while advancing multiple clinical and preclinical programs. Royalty revenue was $18.3 million for the quarter and $50.2 million for the nine months ended June 30, 2025. The company posted a net loss of $18.3 million for the quarter and $63.2 million for the nine months, and had an accumulated deficit of $386.2 million as of June 30, 2025.
Enanta held $204.1 million in cash, cash equivalents and short-term marketable securities and stated that these resources, together with retained royalty cash flows, are expected to fund operations into fiscal 2028. The company recorded a $147.7 million liability related to a $200.0 million royalty sale transaction and continues to recognize 100% of HCV royalties as revenue. Clinical updates include positive pediatric topline results for zelicapavir, completion of enrollment in a Phase 2b high-risk adult zelicapavir study (topline expected September 2025), positive Phase 2a challenge results for EDP-323, Phase 2 results for EDP-235, and progression of immunology programs (KIT and STAT6). The company has appealed a district court decision invalidating a patent asserted against Pfizer; appeal briefs have been filed.